Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Barrett Esophagus 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × INDUSTRY × rofecoxib × Clear all
NCT00060476 2017-05-09

Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)

Merck Sharp & Dohme LLC

Phase 3 Completed
15,000 enrolled
Genitourinary

Prostatic Neoplasms

NCT00637988 2011-01-21

Barrett's Esophagus - 315 - 3 Way Cross Over

AstraZeneca

Phase 4 Completed
32 enrolled
Gastrointestinal

Barrett Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡